BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIVI BioVie Inc

Trading 05-04 12:45:44 EDT

1.74

+0.06

+3.56%

High1.77	Low1.68	Vol111.99K
Open1.70	D1 Closing1.68	Amplitude5.36%
Mkt Cap13.01M	Tradable Cap12.95M	Total Shares7.48M
T/O193.00K	T/O Rate1.50%	Tradable Shares7.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIVI","market":"US","secType":"STK","nameCN":"BioVie Inc","latestPrice":1.7398,"timestamp":1777913056697,"preClose":1.68,"halted":0,"volume":111994,"delay":0,"changeRate":0.03559523809523814,"floatShares":7443300,"shares":7477100,"eps":-5.1345,"marketStatus":"Trading","change":0.0598,"latestTime":"05-04 12:45:44 EDT","open":1.7,"high":1.77,"low":1.68,"amount":192998.7786258,"amplitude":0.053571,"askPrice":1.75,"askSize":300,"bidPrice":1.72,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-5.1345,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777924800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.68,"preHourTrading":{"tag":"盘前","latestPrice":1.7,"preClose":1.68,"latestTime":"09:29 EDT","volume":1138,"amount":1962.3400018,"timestamp":1777901369021,"change":0.02,"changeRate":0.011905,"amplitude":0.029762},"postHourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.68,"latestTime":"19:17 EDT","volume":41585,"amount":72747.135,"timestamp":1777677436297,"change":0.05,"changeRate":0.029762,"amplitude":0.041667},"volumeRatio":2.227454,"impliedVol":1.6378,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BIVI/tweets","defaultTab":"tweets","newsList":[{"id":"2630396168","title":"BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396168","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396168?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:00","pubTimestamp":1777291200,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., April  27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurod","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281541/0/en/BioVie-to-Host-Virtual-KOL-Event-to-Discuss-the-Phase-2-Study-of-Bezisterim-for-the-Treatment-of-Parkinson-s-Disease-ahead-of-Topline-Data-in-2Q26-on-May-7-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139","KOL","HST","BK4585","BK4181","BK4588","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627444513","title":"BioVie SUNRISE-PD bezisterim abstract accepted for presentation at 2026 AAN meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627444513","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627444513?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:05","pubTimestamp":1776168301,"startTime":"0","endTime":"0","summary":"BioVie disclosed acceptance of an abstract from its SUNRISE-PD study of bezisterim  in early Parkinson’s disease for presentation at American Academy of Neurology annual meeting in Chicago on April 18-22, 2026.Poster presentation is scheduled for April 20, covering baseline demographics and patient characteristics from enrolled participants.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLBYDGt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","BIVI","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014021.USD","SG9999014005.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","NDAQ","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624547393","title":"BioVie publishes corporate presentation on bezisterim pipeline catalysts in Parkinson’s, Long Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2624547393","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624547393?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:27","pubTimestamp":1775082433,"startTime":"0","endTime":"0","summary":"BioVie outlined late-stage clinical priorities for lead asset bezisterim, positioning Parkinson’s disease as near-term focus.Topline data from Parkinson’s Phase 2b trial expected in 2Q26.Exploratory Phase 2 study in Long COVID targets topline data in Summer ’26.Company plans to start Phase 3 program for ascites when funding becomes available.Next Alzheimer’s Phase 3 trial using once-daily bezisterim formulation planned upon securing funding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6Qds7S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131074","title":"BioVie to present SUNRISE-PD bezisterim poster at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131074?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:05","pubTimestamp":1773317108,"startTime":"0","endTime":"0","summary":"BioVie said an abstract from its SUNRISE-PD study will be presented at the AD/PD 2026 Advances in Science & Therapy annual meeting in Copenhagen, Denmark. The conference is scheduled for March 17-21, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL93sG1t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","NDAQ","SG9999014013.SGD","BIVI","SG9999014005.SGD","IE00BGHQF748.EUR","LU0314104364.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4139","BK4112","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618317361","title":"BioVie Announces Abstract Accepted for Presentation at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618317361","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618317361?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316800,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., March  12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3254576/0/en/BioVie-Announces-Abstract-Accepted-for-Presentation-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","AD","BK4139","LU1169589451.USD","BK4023","BK4132","PD","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613782834","title":"BioVie to Host Live Investor Webinar and Q&A Session with CEO Cuong Do","url":"https://stock-news.laohu8.com/highlight/detail?id=2613782834","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613782834?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:04","pubTimestamp":1771851857,"startTime":"0","endTime":"0","summary":"BioVie to Host Live Investor Webinar and Q&A Session with CEO Cuong Do               BioVie Inc. will host a live investor webinar and Q&A session on March 4, 2026 at 4:15 p.m. ET, featuring President","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL6bhBX6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014021.USD","BK4585","LU0314104364.USD","NDAQ","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014039.USD","SG9999014005.SGD","BIVI","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613378249","title":"Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4","url":"https://stock-news.laohu8.com/highlight/detail?id=2613378249","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613378249?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:00","pubTimestamp":1771851600,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., Feb.  23, 2026  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3242573/0/en/Join-Biovie-s-Exclusive-Live-Investor-Webinar-and-Q-A-Session-on-March-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610992786","title":"BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2610992786","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610992786?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901200,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., Feb.  12, 2026  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurod","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/12/3237164/0/en/BioVie-Announces-Abstracts-Accepted-for-Presentation-at-the-2026-American-College-of-Psychiatrists-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","BK4107","AFG","ACP","BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606211055","title":"BRIEF-Option Therapeutics Files For IPO Of 2.3 Million Shares Of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2606211055","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606211055?lang=en_us&edition=fundamental","pubTime":"2026-01-26 19:06","pubTimestamp":1769425612,"startTime":"0","endTime":"0","summary":"BRIEF-Option Therapeutics Files For IPO Of 2.3 Million Shares Of Common Stock - SEC FilingJan 26  - BioVie Inc BIVI.O:OPTION THERAPEUTICS INC - FILES FOR IPO OF 2.3 MILLION SHARES OF COMMON STOCK  - SEC FILINGOPTION THERAPEUTICS INC - IPO PRICE EXPECTED BETWEEN $10.00 AND $12.00 PER SHARE - SEC FILINGOPTION THERAPEUTICS INC - INTENDS TO LIST ON NYSE AMERICAN UNDER SYMBOL \"OPTN\" - SEC FILINGOPTION THERAPEUTICS INC SAYS THINKEQUITY IS THE UNDERWRITER TO IPOSource text: [ID:n0001520138-26-000041]Further company coverage: BIVI.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YO1GI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606117942","title":"Option Therapeutics Inc Says Thinkequity Is the Underwriter to IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2606117942","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606117942?lang=en_us&edition=fundamental","pubTime":"2026-01-26 19:03","pubTimestamp":1769425436,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YO1GI:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602977535","title":"BioVie Inc. unveils new data on bezisterim's potential in Parkinson's and Alzheimer's therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2602977535","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602977535?lang=en_us&edition=fundamental","pubTime":"2026-01-11 02:53","pubTimestamp":1768071205,"startTime":"0","endTime":"0","summary":"BioVie Inc. has released a corporate presentation detailing updates on its lead asset, bezisterim , a small molecule targeting TNF-α-mediated inflammation. Clinical trials have shown that bezisterim may reduce inflammation and insulin resistance, improve motor control in Parkinson’s disease patients, and support cognitive function in Alzheimer’s disease. The company is prioritizing the completion of a Phase 2b trial for Parkinson’s disease with topline data expected in the second quarter of 2026, and a Phase 2 exploratory trial for Long Covid, with topline readout anticipated in summer 2026. BioVie also highlighted plans for a Phase 3 ascites trial and a new Phase 3 Alzheimer’s trial, pending additional funding. Bezisterim has demonstrated the ability to cross the blood-brain barrier and has not shown safety issues in pre-clinical and Phase 2 trials. You can access the full presentation through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260110:nNDL7vWGc4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601364500","title":"BioVie Completes Enrollment for Phase 2 SUNRISE-PD Trial Testing Bezisterim in Early Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364500","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364500?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:02","pubTimestamp":1767877378,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDLWMC6y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","NDAQ","BK4585","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","SG9999014021.USD","BK4139","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","BK4588","BIVI","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601378364","title":"BioVie Inc - Topline Results From Sunrise-Pd Trial Expected in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601378364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601378364?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA3YXWFN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601364892","title":"BioVie Completes Enrollment in Phase 2 Sunrise-Pd Trial in Early Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364892","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364892?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877206,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA3YXWFN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590937365","title":"Halozyme Therapeutics Elects Jim Lang to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590937365","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590937365?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:05","pubTimestamp":1765227935,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics Inc. has announced the election of Jim Lang to its Board of Directors. Lang brings over 30 years of executive experience in healthcare, life sciences, business services, and data analytics. He currently serves on the boards of Biovie, Inc., OptimizeRx Corporation, and EVERSANA, where he was most recently CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLbYFWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","LU0053671581.USD","BK4139","OPRX","BIVI","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584949069","title":"Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949069","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949069?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:00","pubTimestamp":1763557200,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., Nov.  19, 2025  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3190852/0/en/Join-Biovie-s-Exclusive-Live-Investor-Webinar-and-Q-A-Session-on-December-9.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioviepharma.com","stockEarnings":[{"period":"1week","weight":0.12},{"period":"1month","weight":0.2174},{"period":"3month","weight":0.4737},{"period":"6month","weight":-0.04},{"period":"1year","weight":-0.8051},{"period":"ytd","weight":0.4483}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.005325},{"month":2,"riseRate":0.5,"avgChangeRate":0.259645},{"month":3,"riseRate":0.625,"avgChangeRate":-0.036628},{"month":4,"riseRate":0.375,"avgChangeRate":0.025089},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.09284},{"month":6,"riseRate":0.5,"avgChangeRate":0.43449},{"month":7,"riseRate":0.5,"avgChangeRate":0.320477},{"month":8,"riseRate":0.25,"avgChangeRate":-0.209827},{"month":9,"riseRate":0.375,"avgChangeRate":-0.162595},{"month":10,"riseRate":0.375,"avgChangeRate":0.201324},{"month":11,"riseRate":0.5,"avgChangeRate":-0.005666},{"month":12,"riseRate":0.25,"avgChangeRate":-0.131533}],"exchange":"NASDAQ","name":"BioVie Inc","nameEN":"BioVie Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioVie Inc(BIVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioVie Inc,BIVI,BioVie Inc股票,BioVie Inc股票老虎,BioVie Inc股票老虎国际,BioVie Inc行情,BioVie Inc股票行情,BioVie Inc股价,BioVie Inc股市,BioVie Inc股票价格,BioVie Inc股票交易,BioVie Inc股票购买,BioVie Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioVie Inc(BIVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction